upadacitinib + topical corticosteroids

Upadacitinib + topical corticosteroids is a **combination therapy** used primarily for the treatment of moderate-to-severe atopic dermatitis in adolescents and adults. Upadacitinib is an orally administered, selective Janus kinase 1 (JAK1) inhibitor that modulates intracellular signaling in the JAK/STAT pathway, resulting in diminished transcription of pro-inflammatory cytokines central to the pathogenesis of autoimmune and inflammatory diseases. Topical corticosteroids are synthetic glucocorticoid molecules that operate by activating the glucocorticoid receptor, reducing inflammation by suppressing multiple inflammatory mediators at the site of application. Together, this combination provides both systemically and locally acting anti-inflammatory effects, resulting in greater improvements in clinical endpoints (e.g., EASI-75 response) compared to either agent alone or placebo in the treatment of moderate-to-severe atopic dermatitis. This combination is supported by phase 3 evidence and is recommended when systemic therapy is indicated[1][3][5].